55 results
8-K
EX-99.1
IGMS
IGM Biosciences Inc
17 Apr 24
IGM Biosciences Announces Refocusing of Sanofi Collaboration
8:34am
/inflammation targets. IGM will retain global rights to its proprietary technology related to the oncology targets nominated by Sanofi under the collaboration … to these oncology targets, our top internal priorities remain our clinical-stage oncology and autoimmune programs."
Terms of the Collaboration
8-K
EX-99.1
IGMS
IGM Biosciences Inc
7 Mar 24
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:10pm
and immunology and inflammation targets. For more information, please visit www.igmbio.com.
Cautionary Note Regarding Forward-Looking Statements
This press
8-K
EX-99.1
IGMS
IGM Biosciences Inc
8 Dec 23
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
4:05pm
to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and immunology and inflammation targets. For more information
8-K
EX-99.1
fsmhy4nxmgijrcl3l0cz
13 Nov 23
IGM Biosciences Announces Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
yoc xyoaojcis
3 Oct 23
Departure of Directors or Certain Officers
4:14pm
8-K
EX-99.1
wqdodr9
3 Aug 23
IGM Biosciences Announces Second Quarter 2023 Financial Results
4:13pm
424B5
cmfitp220kl5zfcg
23 Jun 23
Prospectus supplement for primary offering
4:35pm
FWP
8qcjd fns2uwc87t
22 Jun 23
Free writing prospectus
8:09am
424B5
5buz mfffp3m
22 Jun 23
Prospectus supplement for primary offering
6:19am
FWP
wqi1cy50 0nsx
21 Jun 23
Free writing prospectus
7:00pm
8-K
EX-99.1
z54f14n3
21 Jun 23
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
4:59pm
8-K
EX-99.1
5fbfhhtu mxfx8
12 May 23
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:06am
8-K
EX-99.1
4w7b40
30 Mar 23
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
4:06pm